Discovery of Potent and Selective THRβ Agonists Based on an N -Benzoylglycine Scaffold for the Treatment of Metabolic Disorders
Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 19279-19298
DOI: 10.1021/acs.jmedchem.6c01599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.07.2026. Verfasst von Yue Wu und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, Department of Chemistry, China Pharmaceutical Univ…. Hauptthemen laut MEDLINE: Glycine, Metabolic Diseases, Thyroid Hormone Receptors beta, Drug Discovery. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Basic Research Program of Jiangsu Province.
Abstract (Originalsprache)
Metabolic disorders, including obesity, dyslipidemia, and metabolic dysfunction-associated steatohepatitis (MASH), pose a growing health burden with limited pharmacological options. Thyroid hormone receptor β (THRβ) is a liver-enriched nuclear receptor that regulates lipid metabolism, mitochondrial function, and energy homeostasis, making it a promising therapeutic target. Guided by structural insights, we designed an N-benzoylglycine scaffold as a new chemotype, which provides selectivity for the THRβ receptor against THRα while preserving key interactions with the arginine-rich positively charged pocket. Conformational restriction was introduced to maintain a near-orthogonal orientation that optimizes ligand insertion and hydrogen-bonding with His435. Among the series, compound 18 (ZG-2585) exhibited potent and selective THRβ activation and favorable pharmacokinetic profiles. In a western-diet-induced metabolic disorder mouse model, oral administration of ZG-2585 improved body weight, hepatic steatosis, and lipid accumulation. These results establish the N-benzoylglycine scaffold as a promising chemotype for developing selective, orally active THRβ agonists for metabolic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Design and Optimization, Department of Chemistry, China Pharmaceutical University, Nanjing211198, China.
- Department of Pharmaceutical Engineering, China Pharmaceutical University, Nanjing211198, China.
- Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong SAR999077, China.
ORCID-Profile: Yue Wu, Wei Shen Aik, Xiang Li, Xiaojin Zhang
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Basic Research Program of Jiangsu Province
- Fundamental Research Funds for the Central Universities
- Innovative Drug Research and Development National Science and Technology Major Project
Zitieren
APA
Wu, Y., Zhang, L., Li, X., Cao, R., Han, S., Li, S., Aik, W. S., Zhang, H., Yang, P., Bing, T., Yang, L., Yang, F., Li, X., & Zhang, X. (2026). Discovery of Potent and Selective THRβ Agonists Based on an N -Benzoylglycine Scaffold for the Treatment of Metabolic Disorders. Journal of Medicinal Chemistry, 69(15), 19279-19298. https://doi.org/10.1021/acs.jmedchem.6c01599
Vancouver
Wu Y, Zhang L, Li X, Cao R, Han S, Li S, et al. Discovery of Potent and Selective THRβ Agonists Based on an N -Benzoylglycine Scaffold for the Treatment of Metabolic Disorders. Journal of Medicinal Chemistry. 2026;69(15):19279-19298. doi:10.1021/acs.jmedchem.6c01599
BibTeX
@article{Wu2026,
author = {Wu, Yue and Zhang, Linjian and Li, Xiao and Cao, Ruiheng and Han, Shuang and Li, Shanrui and Aik, Wei Shen and Zhang, Haoshu and Yang, Peiyao and Bing, Tiande and Yang, Le and Yang, Fulai and Li, Xiang and Zhang, Xiaojin},
title = {Discovery of Potent and Selective THRβ Agonists Based on an N -Benzoylglycine Scaffold for the Treatment of Metabolic Disorders},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {15},
pages = {19279--19298},
doi = {10.1021/acs.jmedchem.6c01599}
}
EUVIMED